San Juan del Rio, Queretaro

Unidad de Medicina Especializada SMA

COVID-19

Severe Acute Respiratory Syndrome

Type 2 Diabetes Mellitus

Diabetes Mellitus

Coronavirus Infections

Ertugliflozin

PF-04971729

INO-4800

MK-8835

MK-8835-059

CureVac

Inovio Pharmaceuticals

Merck Sharp & Dohme (MSD)

condition

allSponsorName

Pfizer

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Unidad de Medicina Especializada SMA | San Juan del Rio, Queretaro

Site insights

Work at this site?

Active trials

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Trial sponsors